Evaluation of the HARM for the Detection of a Cerebral Ischemia in TIA/TNA Patients
NCT ID: NCT03555643
Last Updated: 2024-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
96 participants
OBSERVATIONAL
2017-11-01
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TIA is defined as a transient focal neurological deficit with a probably cerebrovascular cause. In contrast, TNA is defined as a transient non-focal neurological deficit with multiple causes, including cerebrovascular. The clinical diagnosis of TIA is often flawed and the delineation of TIA and TNA can be difficult. MRI is the most important diagnostic method for the detection or exclusion of cerebral ischemia in patients with TIA/TNA in daily clinical practice. However, on diffusion-weighted imaging (DWI) approximately two-thirds of TIA cases and only one-fifth of TNA cases demonstrate acute cerebral ischemia. Supplementary perfusion-weighted imaging (PWI) scans can only slightly increase this percentage. The well-known HARM could prove to be complementary to DWI and PWI and close or at least reduce the existing gap. In the case of TNA in particular, this could be of clinical relevance in order to avoid mistreatment or even dismissal without further clarification after supposedly inconspicuous imaging.
Therefore, the aim of this study is to record the incidence of HARM in a statistically significant number of cases of patients with TIA and TNA and to investigate relationships with symptom duration and anatomical localization. In addition, the dynamics of contrast enhancement in the subarachnoid space in TIA and TNA cases with HARM will be analyzed in detail.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carotid Plaque Imaging in Acute Stroke
NCT01284933
The Recurrence Study
NCT03244215
Biomarkers for the Diagnosis of Transient Ischemic Attack
NCT02799511
Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage.
NCT06804421
Biomarker for Rapid Diagnosis of Hemispheric Stroke
NCT00916864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
transient ischemic attack (TIA)
Patients with transient ischemic attack
No interventions assigned to this group
transient neurological attack (TNA)
Patients with transient neurological attack
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* transient non-focal neurological symptoms (confusion, dizziness, memory deficits, gait insecurity, bilateral weakness, etc.)
* MRI examination possible within 24 hours of symptoms
* able to give informed consent
Exclusion Criteria
* symptoms lasting more than \> 24 h
* clinical suspicion of other cause of symptoms (seizures, intoxication, hypoglycemia, psychogenic)
* contraindications for MRI (pacemaker, metallic splinter, cochlear implants, etc.)
* unable to give consent
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitätsmedizin Mannheim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alex Förster
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex Förster, MD
Role: PRINCIPAL_INVESTIGATOR
Universitätsmedizin Mannheim, Dept. of Neuroradiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsmedizin Mannheim
Mannheim, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-591N-MA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.